AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Public ClinicalTrials.gov record NCT02143466. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).
Study identification
- NCT ID
- NCT02143466
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 344 participants
Conditions and interventions
Conditions
Interventions
- Part A - AZD9291 in combination with AZD6094 Drug
- Part A - AZD9291 in combination with MEDI4736 Drug
- Part A - AZD9291 in combination with continuous selumetinib (Asian subjects) Drug
- Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects) Drug
- Part A - AZD9291 in combination with intermittent selumetinib Drug
- Part B - AZD9291 in combination with AZD6094 Drug
- Part B - AZD9291 in combination with MEDI4736 Drug
- Part B - AZD9291 in combination with selumetinib Drug
- Part C - AZD6094 monotherapy (Japan only) Drug
- Part C - AZD9291 in combination with AZD6094 (Japan only) Drug
- Part D - AZD9291 in combination with AZD6094 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2014
- Primary completion
- Mar 3, 2020
- Completion
- Dec 30, 2026
- Last update posted
- Apr 23, 2026
2014 – 2026
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Atlanta | Georgia | 30329 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02143466, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02143466 live on ClinicalTrials.gov.